lunedì, 4 maggio 2026

Notizie AIOM – anno XVII

23 Settembre 2019

AACR Cancer Progress Report 2019 Released

Sep 18, 2019 - Today, the American Association for Cancer Research (AACR) released the AACR Cancer Progress Report 2019, which highlights how research largely supported by federal investments in the National Institutes of Health (NIH) is spurring improvements in public health ...
Leggi tutto

23 Settembre 2019

Cancer Survival, Incidence, and Mortality in Seven High-Income Countries From 1995–2014

Sep 19, 2019 - As reported by Arnold and colleagues in The Lancet Oncology, the International Cancer Benchmarking Partnership Cancer Survival in High-Income Countries (SURVMARK-2) project has found general improvement in cancer survival between 1995 and 2014 in Australia, ...
Leggi tutto

23 Settembre 2019

FDA Grants Enfortumab Vedotin Priority Review for Urothelial Cancer

Sep 16, 2019 - The FDA has granted a priority review designation to a biologics license application (BLA) for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor ...
Leggi tutto

23 Settembre 2019

FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancer

Sep 18, 2019 - The FDA has approved apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer. The approval is based on findings from the phase III TITAN trial (NCT02489318), which showed that apalutamide plus androgen deprivation therapy ...
Leggi tutto

23 Settembre 2019

The FDA Could Help Address Financial Toxicity During the Approval Process

Sep 21, 2019 - Cancer is among the costliest medical conditions to treat in the United States, causing many patients to experience “financial toxicity.” This term is often used to describe how out-of-pocket costs can cause financial distress to patients. One ...
Leggi tutto

23 Settembre 2019

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019

Sep 20, 2019 - EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its September 2019 meeting. The Committee recommended granting a marketing authorisation for gilteritinib for the treatment of adult patients who have relapsed or refractory ...
Leggi tutto

23 Settembre 2019

Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade

Microsatellite instability (MSI) and high tumor mutation burden (TMB-High) are promising pan-tumor biomarkers used to select patients for treatment with immune checkpoint blockade; however, real-time sequencing of unresectable or metastatic solid tumors is often challenging. ...
Leggi tutto

23 Settembre 2019

Association of Early Palliative Care Use With Survival and Place of Death Among Patients With Advanced Lung Cancer Receiving Care in the Veterans Health Administration

Palliative care is a patient-centered approach associated with improvements in quality of life; however, results regarding its association with a survival benefit have been mixed, which may be a factor in its underuse. To assess whether early palliative care is associated ...
Leggi tutto

23 Settembre 2019

17 settembre 2019 – Sperimentazioni cliniche: AIFA e le strutture di fase I fanno il punto su stato dell’arte e sfide future

23 Settembre 2019

17 settembre 2019 – “Qualità, sicurezza ed efficacia dei farmaci sono un obiettivo prioritario per AIFA”